A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat i oczekiwana długość życia co najmniej 12 tygodni
- •Nowotwór potwierdzony badaniami histologicznym lub cytologicznym
- •Choroba odporna na standardowe leczenie lub brak dostępnego efektywnego leczenia
- •Dobrze funkcjonujące nerki, wątroba i szpik kostny zgodnie z wymogami badania
- •Chęć dostarczenia próbek nowotworu i krwi do analiz
- •Zgoda na stosowanie antykoncepcji zgodnie z protokołem badania
- •Podpisana świadoma zgoda na uczestnictwo w badaniu
- •U pacjentów z rakiem prostaty: utrzymanie poziomu testosteronu zgodnie z wymogami badania
✗ Disqualifies
- •Historia przeszczepu narządu stałego lub szpiku kostnego od innego dawcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (80)
H. Lee Moffitt Cancer Center & Research Institute
Tampa, United States
Winship Cancer Institute of Emory University
Atlanta, United States
University of Chicago Medical Center
Chicago, United States
Loyola University Medical Center
Maywood, United States
University of Maryland Greenebaum Cancer Center
Baltimore, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
University of Michigan Hospitals
Ann Arbor, United States
South Texas Accelerated Research Therapeutics (START) - Midwest Location
Grand Rapids, United States
Hackensack University Medical Center
Hackensack, United States
Roswell Park Cancer Institute
Buffalo, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, United States
Memorial Sloan Kettering Cancer Center - NYC
New York, United States
Weill Medical College of Cornell University
New York, United States
University of Rochester Medical Center, James P. Wilmot Cancer Center
Rochester, United States
Montefiore Medical Center, Montefiore Medical Center Laboratories
The Bronx, United States
University of Cincinnati Medical Center
Cincinnati, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, United States
South Texas Accelerated Research Therapeutics
San Antonio, United States
University of Virginia Health System
Charlottesville, United States
Swedish Cancer Institute
Seattle, United States
Fred Hutchinson Cancer Center
Seattle, United States
CHU Bordeaux Hopital Saint Andre
Bordeaux, France
CLCC Institut Bergonie
Bordeaux, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
CHU Nantes Hopital Hotel Dieu
Nantes, France
CHU Nantes Hopital Nord Laennec
Saint-Herblain, France
Hopital Hautepierre
Strasbourg, France
Gustave Roussy
Villejuif, France
Irccs University Hospital of Bologna
Bologna, Italy
National Cancer Institute, IRCCS
Milan, Italy
National Cancer Institute, IRCCS
Milan, Italy
European Institute of Oncology (IEO), IRCCS
Milan, Italy
European Institute of Oncology (IEO), IRCCS
Milan, Italy
Humanitas San Pio X
Milan, Italy
University Polyclinic Foundation "Agostino Gemelli" - IRCCS
Roma, Italy
Gruppo Humanitas - Humanitas Research Hospital - Cancer Center
Rozzano, Italy
University Teaching Centre, Early Clinical Trials Unit
Gdansk, Poland
Pratia MCM Krakow
Krakow, Poland
Polish Mother's Memorial Hospital-Research Institute
Lodz, Poland
Pratia - Poznan
Poznan, Poland
University Teaching Hospital in Poznan, Department of Gynecologic Oncology
Poznan, Poland
Maria Sklodowska-Curie - National Research Institute of Oncology
Warsaw, Poland
Keimyung University - Dongsan Medical Center
Daegu, South Korea
National Cancer Center
Goyang-si, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
University Hospital Vall d'Hebron
Barcelona, Spain
Hospital Clinic of Barcelona
Barcelona, Spain
University Hospital of Girona Dr. Josep Trueta
Girona, Spain
Catalan Institute of Oncology, Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain
University Clinic of Navarra - Madrid
Madrid, Spain
University Hospital Ramon y Cajal
Madrid, Spain
University Hospital Clinical San Carlos, Department of Medical Oncology
Madrid, Spain
University Hospital Foundation Jimenez Diaz
Madrid, Spain
University Hospital 12 de Octubre
Madrid, Spain
University Hospital Quiron Madrid
Madrid, Spain
University Hospital Puerta de Hierro Majadahonda
Majadahonda, Spain
University Hospital Son Espases
Palma, Spain
University Clinic of Navarra - Pamplona
Pamplona, Spain
Parc Tauli Health Corporation
Sabadell, Spain
University Clinical Hospital of Salamanca
Salamanca, Spain
University Hospital Complex of Santiago (CHUS)
Santiago de Compostela, Spain
University Hospital Virgen del Rocio (HUVR)
Seville, Spain
Valencia Oncology Institute (IVO)
Valencia, Spain
University and Polytechnic Hospital La Fe
Valencia, Spain
Royal United Hospital, Department of Oncology/Hematology
Bath, United Kingdom
Leicester Royal Infirmary
Leicester, United Kingdom
Royal Marsden Hospital - London
London, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
The Christie NHS Foundation Trust, Department of Medical Oncology
Manchester, United Kingdom
Churchill Hospital
Oxford, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Royal Marsden Hospital - Sutton
Sutton, United Kingdom
Musgrove Park Hospital
Taunton, United Kingdom
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.